Edition:
India

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

16.65USD
18 Sep 2020
Change (% chg)

$1.06 (+6.80%)
Prev Close
$15.59
Open
$15.86
Day's High
$17.13
Day's Low
$15.66
Volume
887,064
Avg. Vol
294,642
52-wk High
$26.53
52-wk Low
$5.51

Latest Key Developments (Source: Significant Developments)

Meridian Bioscience Reports Fiscal Q3 2020 Operating Results
Friday, 7 Aug 2020 

Aug 7 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE REPORTS FISCAL THIRD QUARTER 2020 OPERATING RESULTS – BEST QUARTER IN COMPANY HISTORY – RAISES FULL YEAR GUIDANCE.Q3 REVENUE ROSE 75 PERCENT TO $84.8 MILLION.Q3 GAAP EARNINGS PER SHARE $0.64.Q3 REVENUE ESTIMATE $66 MILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE ESTIMATE $0.23 -- REFINITIV IBES DATA.RAISING OUR GUIDANCE FOR YEAR.SEES FY2020 NET REVENUES CONSOLIDATED $245 MILLION TO $250 MILLION.SEES FY2020 ADJUSTED EARNINGS PER SHARE $1.01 TO $1.05.  Full Article

Meridian Bioscience Reports Second Quarter 2020 Operating Results Raises Guidance On Strength Of Covid-19 Related Products
Friday, 8 May 2020 

May 8 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE REPORTS SECOND QUARTER 2020 OPERATING RESULTS; RAISES GUIDANCE ON STRENGTH OF COVID-19 RELATED PRODUCTS.Q2 REVENUE ROSE 14 PERCENT TO $57.3 MILLION.Q2 GAAP EARNINGS PER SHARE $0.22.RAISING FISCAL 2020 GUIDANCE.SEES 2020 CONSOLIDATED NET REVENUES $230 MILLION TO $236 MILLION.QTRLY ADJUSTED EARNINGS PER SHARE $0.23.SEES 2020 LIFE SCIENCE NET REVENUE $110 MILLION - $114 MILLION.SEES 2020 ADJUSTED EPS $0.70 TO $0.75.MERIDIAN BIOSCIENCE - 2020 GUIDANCE CONSIDERS THAT SPENDING ON CLINICAL TRIALS IN FISCAL 2020 WILL BE LOWER THAN ORIGINALLY ANTICIPATED.MERIDIAN BIOSCIENCE - COVID-19 PANDEMIC HAS PAUSED MOST OF CLINICAL TRIAL SITES, AFFECTED ABILITY TO COLLECT PATIENT SPECIMENS.  Full Article

Meridian Bioscience Announces Preliminary Q2 2020 Revenue Results
Thursday, 2 Apr 2020 

April 2 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE ANNOUNCES BETTER-THAN-EXPECTED PRELIMINARY SECOND QUARTER FISCAL 2020 REVENUE RESULTS WITH DOUBLE-DIGIT GROWTH.SEES Q2 2020 REVENUE ABOUT $57 MILLION.INCREASE IN Q2 REVENUE DRIVEN PRIMARILY BY LIFE SCIENCE SEGMENT REVENUES.NOT UPDATING ITS FISCAL YEAR 2020 GUIDANCE AT THIS TIME.HAS NOT EXPERIENCED ANY MATERIAL SUPPLY CHAIN ISSUES TO DATE.MANY OF CO'S CLINICAL TRIAL PARTNERS HAVE SUSPENDED OPERATIONS, WHICH WILL LIKELY RESULT IN DELAYS FOR PRODUCTS IN PIPELINE.MERIDIAN BIOSCIENCE - EXPECT CLINICAL TRIAL PARTNERS SUSPENDING OPERATIONS TO REDUCE FISCAL 2020 RESEARCH AND DEVELOPMENT SPENDING BELOW PREVIOUSLY COMMUNICATED AMOUNTS.  Full Article

Meridian Bioscience Reports First Quarter Fiscal 2020 Operating Results And Reaffirms 2020 Guidance
Friday, 7 Feb 2020 

Feb 7 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE REPORTS FIRST QUARTER FISCAL 2020 OPERATING RESULTS AND REAFFIRMS 2020 GUIDANCE.Q1 GAAP EARNINGS PER SHARE $0.07.Q1 ADJUSTED EARNINGS PER SHARE $0.10.QTRLY NET REVENUES $47.4 MILLION VERSUS $51.5 MILLION.MERIDIAN BIOSCIENCE - IN JAN, BEGAN SHIPPING MOLECULAR REAGENTS TO IVD MANUFACTURING CUSTOMERS IN CHINA TO HELP COMBAT CORONAVIRUS OUTBREAK."EXPECT IMPROVED PERFORMANCE IN REMAINING QUARTERS OF FISCAL YEAR".SHIPPING MOLECULAR REAGENTS TO IVD MANUFACTURING CUSTOMERS IN CHINA NOT INCLUDED IN OUR Q1 RESULTS.MERIDIAN BIOSCIENCE - LIFE SCIENCE SEGMENT REVENUES FOR QUARTER REFLECTED LOWER ORDERING PATTERNS WITH TOP IVD MANUFACTURING CUSTOMERS.  Full Article

Meridian Bioscience Reports Fourth Quarter And Full-Year Fiscal 2019 Operating Results
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL-YEAR FISCAL 2019 OPERATING RESULTS AND PROVIDES FISCAL 2020 GUIDANCE.Q4 ADJUSTED EARNINGS PER SHARE $0.13.Q4 GAAP EARNINGS PER SHARE $0.10.Q4 EARNINGS PER SHARE ESTIMATE $0.09 -- REFINITIV IBES DATA.  Full Article

Meridian Bioscience Reports Q4 Results
Thursday, 7 Nov 2019 

Nov 7 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL-YEAR FISCAL 2019 OPERATING RESULTS AND PROVIDES FISCAL 2020 GUIDANCE.QTRLY CONSOLIDATED REVENUE DECREASED 4% TO $50.8 MILLION.Q4 REVENUE VIEW $50.6 MILLION -- REFINITIV IBES DATA.SEES FY REVENUE CONSOLIDATED FLAT TO DOWN 3%.SEES FY ADJUSTED EARNINGS PER SHARE $0.28 TO $0.34.FY2019 EARNINGS PER SHARE VIEW $0.64, REVENUE VIEW $200.7 MILLION -- REFINITIV IBES DATA.FY2020 EARNINGS PER SHARE VIEW $0.51, REVENUE VIEW $201.8 MILLION -- REFINITIV IBES DATA.FY 2019 REVENUE DECREASED 6% TO $201.0 MILLION.FY EARNINGS PER SHARE $0.57.SEES FY REVENUE DIAGNOSTICS SEGMENT DOWN 3% TO 5%.SEES FY ADJUSTED OPERATING MARGIN CONSOLIDATED 9% TO 10%.  Full Article

Meridian Submits Curian Analyzer And The Curian HpSA Assay To The FDA
Wednesday, 6 Nov 2019 

Nov 6 (Reuters) - Meridian Bioscience Inc ::MERIDIAN SUBMITS CURIAN™ ANALYZER AND THE CURIAN™ HPSA ASSAY TO THE FDA.  Full Article

Meridian Bioscience Inc says On Oct 1, Promoted Bryan T. Baldasare To CFO Of Co
Friday, 4 Oct 2019 

Oct 4 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE INC - ON OCT 1, PROMOTED BRYAN T. BALDASARE TO CFO OF COMPANY EFFECTIVE IMMEDIATELY.MERIDIAN BIOSCIENCE INC - BALDASARE WILL CONTINUE SERVING AS COMPANY'S PRINCIPAL FINANCIAL AND PRINCIPAL ACCOUNTING OFFICER.  Full Article

Meridian Bioscience Says Co And Eric Rasmussen Entered Into A Separation Agreement
Tuesday, 25 Jun 2019 

June 25 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE INC - ON JUNE 21, 2019, CO AND ERIC S. RASMUSSEN ENTERED INTO A SEPARATION AGREEMENT.MERIDIAN BIOSCIENCE - RASMUSSEN'S LAST DAY OF EMPLOYMENT AS MERIDIAN'S EXECUTIVE VICE PRESIDENT AND CFO SHALL BE JUNE 28, 2019.MERIDIAN BIOSCIENCE INC - EFFECTIVE JUNE 28, 2019, APPOINTED BRYAN T. BALDASARE TO SERVE AS INTERIM CHIEF FINANCIAL OFFICER.  Full Article

Meridian Bioscience Inc says Effective May 24, Entered Into $125 Million Revolving Credit Facility Credit Agreement
Friday, 31 May 2019 

May 31 (Reuters) - Meridian Bioscience Inc ::MERIDIAN BIOSCIENCE INC - EFFECTIVE MAY 24, 2019, CO TOGETHER WITH CERTAIN OF UNITS ENTERED INTO A $125 MILLION REVOLVING CREDIT FACILITY CREDIT AGREEMENT.MERIDIAN BIOSCIENCE INC - CREDIT AGREEMENT REPLACES COMPANY'S LOAN AND SECURITY AGREEMENT DATED AS OF AUGUST 1, 2007.MERIDIAN BIOSCIENCE INC - CREDIT AGREEMENT MAKES AVAILABLE TO CO A REVOLVING CREDIT FACILITY IN AGGREGATE PRINCIPAL AMOUNT NOT TO EXCEED $125 MILLION.MERIDIAN BIOSCIENCE INC - PNC AND FIFTH THIRD ARE COMMITTED LENDERS UNDER CREDIT AGREEMENT.  Full Article

BRIEF-Meridian To Supply Reagents To Make Tens Of Millions Of COVID-19 Antibody Tests Per Month

* MERIDIAN BIOSCIENCE ANNOUNCES IT WILL SUPPLY REAGENTS FOR MANUFACTURING OF TENS OF MILLIONS OF COVID-19 ANTIBODY TESTS PER MONTH Source text for Eikon: Further company coverage: